REFERENCES
1. Castillon G, Chang SC, Moride Y. Global incidence and prevalence of gaucher disease: a targeted literature review. J Clin Med 2022;12:85.
2. Nalysnyk L, Rotella P, Simeone JC, Hamed A, Weinreb N. Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology 2017;22:65-73.
3. Daykin EC, Ryan E, Sidransky E. Diagnosing neuronopathic Gaucher disease: new considerations and challenges in assigning Gaucher phenotypes. Mol Genet Metab 2021;132:49-58.
4. Horowitz M, Braunstein H, Zimran A, Revel-Vilk S, Goker-Alpan O. Lysosomal functions and dysfunctions: molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease. Adv Drug Deliv Rev 2022;187:114402.
5. Hughes D, Mikosch P, Belmatoug N, et al. Gaucher disease in bone: from pathophysiology to practice. J Bone Miner Res 2019;34:996-1013.
6. Rosenbloom BE, Cappellini MD, Weinreb NJ, et al. Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry. Am J Hematol 2022;97:1337-47.
7. Roh J, Subramanian S, Weinreb NJ, Kartha RV. Gaucher disease - more than just a rare lipid storage disease. J Mol Med 2022;100:499-518.
8. Weinreb NJ, Barbouth DS, Lee RE. Causes of death in 184 patients with type 1 Gaucher disease from the United States who were never treated with enzyme replacement therapy. Blood Cells Mol Dis 2018;68:211-7.
9. Revel-Vilk S, Szer J, Mehta A, Zimran A. How we manage Gaucher disease in the era of choices. Br J Haematol 2018;182:467-80.
10. Weinreb NJ, Camelo JS Jr, Charrow J, McClain MR, Mistry P, Belmatoug N. International Collaborative Gaucher Group (ICGG) Gaucher Registry (NCT00358943) investigators. Gaucher disease type 1 patients from the ICGG Gaucher registry sustain initial clinical improvements during twenty years of imiglucerase treatment. Mol Genet Metab 2021;132:100-11.
11. Andrade-Campos MM, de Frutos LL, Cebolla JJ, et al. Identification of risk features for complication in Gaucher's disease patients: a machine learning analysis of the Spanish registry of Gaucher disease. Orphanet J Rare Dis 2020;15:256.
12. Goker-Alpan O. Therapeutic approaches to bone pathology in Gaucher disease: past, present and future. Mol Genet Metab 2011;104:438-47.
13. Grabowski GA, Antommaria AHM, Kolodny EH, Mistry PK. Gaucher disease: basic and translational science needs for more complete therapy and management. Mol Genet Metab 2021;132:59-75.
14. Sam R, Ryan E, Daykin E, Sidransky E. Current and emerging pharmacotherapy for Gaucher disease in pediatric populations. Expert Opin Pharmacother 2021;22:1489-503.
15. Els C, Jackson TD, Kunyk D, et al. Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane reviews. Cochrane Database Syst Rev 2017;10:CD012509.
16. Noori A, Sadeghirad B, Wang L, et al. Comparative benefits and harms of individual opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised trials. Br J Anaesth 2022;129:394-406.
17. Almogi-Hazan O, Or R. Cannabis, the endocannabinoid system and immunity-the journey from the bedside to the bench and back. Int J Mol Sci 2020;21:4448.
18. Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol 2020;16:9-29.
19. Crocq MA. History of cannabis and the endocannabinoid system. Historia del cannabis y del sistema de endocannabinoides. Histoire du cannabis et du système endocannabinoϊde. Dialogues Clin Neurosci 2020;22:223-8.
20. Lowin T, Schneider M, Pongratz G. Joints for joints: cannabinoids in the treatment of rheumatoid arthritis. Curr Opin Rheumatol 2019;31:271-8.
21. Weiss L, Zeira M, Reich S, et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 2006;39:143-51.
22. Gallily R, Yekhtin Z, Hanuš LO. The anti-inflammatory properties of terpenoids from cannabis. Cannabis Cannabinoid Res 2018;3:282-90.
23. Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants 2019;9:21.
24. Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol 2014;24:R453-62.
25. Cherukury HM, Argueta DA, Garcia N, et al. Cannabidiol attenuates hyperalgesia in a mouse model of sickle cell disease. Blood 2023;141:203-8.
26. Mackie K. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 2006;46:101-22.
27. Xin Y, Tang A, Pan S, Zhang J. Components of the endocannabinoid system and effects of cannabinoids against bone diseases: a mini-review. Front Pharmacol 2021;12:793750.
28. Raphael-Mizrahi B, Gabet Y. The cannabinoids effect on bone formation and bone healing. Curr Osteoporos Rep 2020;18:433-8.
29. Lu HC, Mackie K. Review of the endocannabinoid system. Biol Psychiatry Cogn Neurosci Neuroimaging 2021;6:607-15.
30. Florida Cannabis Information. Is CBD oil legal in Florida? Available from: FloridaStateCannabis.org [Last accessed on 22 Aug 2024].
31. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-9.
32. Collin C, Davies P, Mutiboko IK, Ratcliffe S. Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14:290-6.
33. Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010;182:E694-701.
34. Naftali T, Bar-Lev Schleider L, Scklerovsky Benjaminov F, Konikoff FM, Matalon ST, Ringel Y. Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: a randomized controlled trial. PLoS One 2021;16:e0246871.
35. McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 2018;175:225-31.
36. Longo R, Oudshoorn A, Befus D. Cannabis for chronic pain: a rapid systematic review of randomized control trials. Pain Manag Nurs 2021;22:141-9.
37. Fisher E, Moore RA, Fogarty AE, et al. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain 2021;162:S45-66.
38. Arkell TR, Downey LA, Hayley AC, Roth S. Assessment of medical cannabis and health-related quality of life. JAMA Netw Open 2023;6:e2312522.
39. Abuhasira R, Schleider LBL, Mechoulam R, Novack V. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. Eur J Intern Med 2018;49:44-50.
40. Costa B. On the pharmacological properties of Δ9-tetrahydrocannabinol (THC). Chem Biodivers 2007;4:1664-77.
41. Holden SK, Domen CH, Sillau S, Liu Y, Leehey MA. Higher risk, higher reward? Self-reported effects of real-world cannabis use in parkinson's disease. Mov Disord Clin Pract 2022;9:340-50.
42. Chesney E, Oliver D, Green A, et al. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology 2020;45:1799-806.
43. Jones JM. Nearly half of U.S. adults have tried marijuana. Available from: https://news.gallup.com/poll/353645/nearly-half-adults-tried-marijuana.aspx [Last accessed on 22 Aug 2024].
44. ProCon.org. State-by-state recreational marijuana laws. Available from: https://marijuana.procon.org/legal-recreational-marijuana-states-and-dc/ [Last accessed on 22 Aug 2024].
45. Lal S, Prasad N, Ryan M, et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2011;23:891-6.
46. Weiss A, Friedenberg F. Patterns of cannabis use in patients with inflammatory bowel disease: a population based analysis. Drug Alcohol Depend 2015;156:84-9.
47. Buckley MC, Kumar A, Swaminath A. Inflammatory bowel disease and cannabis: a practical approach for clinicians. Adv Ther 2021;38:4152-61.
48. Wipfler K, Simon T, Katz P, et al. Cannabis use among patients in a large US rheumatic disease registry. In: 2019 ACR/ARP annual meeting. Available from: https://acrabstracts.org/abstract/cannabis-use-among-patients-in-a-large-us-rheumatic-disease-registry/ [Last accessed on 22 Aug 2024].
49. Nielsen SW, Ruhlmann CH, Eckhoff L, Brønnum D, Herrstedt J, Dalton SO. Cannabis use among Danish patients with cancer: a cross-sectional survey of sociodemographic traits, quality of life, and patient experiences. Support Care Cancer 2022;30:1181-90.
50. Cousins MM, Mayo C, Devasia T, et al. Cannabis use in patients seen in an academic radiation oncology department. Pract Radiat Oncol 2023;13:112-21.
51. Cousins MM, Jannausch ML, Coughlin LN, Jagsi R, Ilgen MA. Prevalence of cannabis use among individuals with a history of cancer in the United States. Cancer 2021;127:3437-44.
52. Johal H, Devji T, Chang Y, Simone J, Vannabouathong C, Bhandari M. Cannabinoids in chronic non-cancer pain: a systematic review and meta-analysis. Clin Med Insights Arthritis Musculoskelet Disord 2020;13:1179544120906461.
53. Powell A. Medical school’s Kevin hill talks about fearmongering and rosy myths, safe use and addiction. Available from: https://news.harvard.edu/gazette/story/2020/02/professor-explores-marijuanas-safe-use-and-addiction/ [Last accessed on 22 Aug 2024].
54. Gelberg L, Beck D, Koerber J, et al. Cannabis use reported by patients receiving primary care in a large health system. JAMA Netw Open 2024;7:e2414809.
55. Elstein D, Belmatoug N, Deegan P, et al. Development and validation of Gaucher disease type 1 (GD1)-specific patient-reported outcome measures (PROMs) for clinical monitoring and for clinical trials. Orphanet J Rare Dis 2022;17:9.
56. Balwani M, Fuerstman L, Desnick RJ, Buckley B, McGovern MM. Use of complementary and alternative medicine by patients with lysosomal storage diseases. Genet Med 2009;11:722-7.
57. Mistry PK, Balwani M, Charrow J, et al. Real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the international collaborative Gaucher group Gaucher registry. Am J Hematol 2020;95:1038-46.
58. Zimran A, Belmatoug N, Bembi B, et al. GOS study group. Demographics and patient characteristics of 1209 patients with Gaucher disease: descriptive analysis from the Gaucher outcome survey (GOS). Am J Hematol 2018;93:205-12.
59. Weinreb NJ, Finegold DN, Feingold E, et al. Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3). Orphanet J Rare Dis 2015;10:64.
60. Mistry PK, Batista JL, Andersson HC, et al. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the international collaborative Gaucher group (ICGG) Gaucher registry. Am J Hematol 2017;92:929-39.
61. Most Americans favor legalizing marijuana for medical, recreational use. 2024. Available from: www.pewresearch.org/wp-content/uploads/sites/20/2024/03/PP_2024.3.26_marijuana_REPORT.pdf [Last accessed on 22 Aug 2024].
62. Luc MH, Tsang SW, Thrul J, Kennedy RD, Moran MB. Content analysis of online product descriptions from cannabis retailers in six US states. Int J Drug Policy 2020;75:102593.
63. Walker M, Carpino M, Lightfoot D, et al. The effect of recreational cannabis legalization and commercialization on substance use, mental health, and injury: a systematic review. Public Health 2023;221:87-96.
64. Sholler DJ, Schoene L, Spindle TR. Therapeutic efficacy of cannabidiol (CBD): a review of the evidence from clinical trials and human laboratory studies. Curr Addict Rep 2020;7:405-12.
65. Joehanes R, Just AC, Marioni RE, et al. Epigenetic signatures of cigarette smoking. Circ Cardiovasc Genet 2016;9:436-47.
66. Sophocleous A, Robertson R, Ferreira NB, McKenzie J, Fraser WD, Ralston SH. Heavy cannabis use is associated with low bone mineral density and an increased risk of fractures. Am J Med 2017;130:214-21.
67. Ihejirika-Lomedico R, Patel K, Buchalter DB, et al. Non-psychoactive cannabidiol prevents osteoporosis in an animal model and increases cell viability, proliferation, and osteogenic gene expression in human skeletal stem and progenitor cells. Calcif Tissue Int 2023;112:716-26.
68. Miodownik H, Curtis SA, Olivia Ogu U, et al. Frequent health care utilisation and avascular necrosis are associated with cannabis use in adults with sickle cell disease. Br J Haematol 2022;196:e41-4.
69. Urbi B, Corbett J, Hughes I, et al. Effects of cannabis in parkinson's disease: a systematic review and meta-analysis. J Parkinsons Dis 2022;12:495-508.
70. Figura M, Koziorowski D, Sławek J. Cannabis in parkinson’s disease - the patient’s perspective versus clinical trials: a systematic literature review. Neurol Neurochir Pol 2022;56:21-7.
71. Varshney K, Patel A, Ansari S, Shet P, Panag SS. Cannabinoids in treating parkinson’s disease symptoms: a systematic review of clinical studies. Cannabis Cannabinoid Res 2023;8:716-30.
72. Ferreira-Junior NC, Campos AC, Guimarães FS, et al. Biological bases for a possible effect of cannabidiol in Parkinson’s disease. Braz J Psychiatry 2020;42:218-24.
73. Fernández-Moncada I, Eraso-Pichot A, Dalla Tor T, Fortunato-Marsol B, Marsicano G. An enquiry to the role of CB1 receptors in neurodegeneration. Neurobiol Dis 2023;184:106235.
75. Huang J, Huang D, Ruan X, et al. Association between cannabis use with urological cancers: a population-based cohort study and a mendelian randomization study in the UK biobank. Cancer Med 2023;12:3468-76.
